Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets

mAbs

Volumn 9, Issue 7, 2017, Pages 1118-1128

  Gong, Shiyong ^a   Ren, Fang ^a   Wu, Danqing ^a   Wu, Xuan ^a   Wu, Chengbin ^a  

^a EpimAb Biotherapeutics ^*  (China)

Author keywords

Antibody engineering; bispecific antibody; epidermal growth factor receptor; Fabs in tandem immunoglobulin; FIT Ig; hepatocyte growth factor receptor; non small cell lung carcinoma

Indexed keywords

BISPECIFIC ANTIBODY;

HUMAN; IMMUNOLOGY;

ANTIBODIES, BISPECIFIC; HUMANS;

EID: 85026532813     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1345401     Document Type: Article

References (44)

1. Park SS, Ryu CJ, Kang YJ, Kashmiri SV, Hong HJ. Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol 2000; 37:1123-30; PMID:11451417; https://doi.org/10.1016/S0161-5890(01)00027-X
2. Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: Development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015; 67:51-62; PMID:25303306; https://doi.org/10.1002/art.38896
3. Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res 2016; 76:3942-53; PMID:27216193; https://doi.org/10.1158/0008-5472.CAN-15-2833
4. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; https://doi.org/10.1158/0008-5472.CAN-09-0547
5. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18:1570-4; PMID:23023498; https://doi.org/10.1038/nm.2942
6. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; https://doi.org/10.1126/science.1158545
7. Sheridan C. Despite slow progress, bispecifics generate buzz. Nat Biotechnol 2016; 34:1215-7; PMID:27926715; https://doi.org/10.1038/nbt1216-1215
8. Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs 2017; 9:182-212; PMID:28071970; https://doi.org/10.1080/19420862.2016.1268307
9. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; https://doi.org/10.1038/nbt.2621
10. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; https://doi.org/10.1073/pnas.1019002108
11. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; https://doi.org/10.1038/nbt1345
12. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; https://doi.org/10.1016/j.molimm.2015.01.003
13. Barrett A. Anti-IL-17 antibodies. International Publication Number: WO2007/070750A1 2006.
14. Jesper P. Anti-human Interleukin-20 antibodies. International Publication Number: WO2010/000721 2009.
15. Burmester GR, Feist E, Dörner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10:77-88; PMID:24217582; https://doi.org/10.1038/nrrheum.2013.168
16. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105:692-7; PMID:18180459; https://doi.org/10.1073/pnas.0707270105
17. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88; PMID:20129249; https://doi.org/10.1016/j.ccr.2009.11.022
18. Jakobovits A. Human monoclonal antibodies to epidermal growth factor receptor. 1997; Patent No.: US6235883.
19. Michaud NR. Antibodies to cMet. 2004; Patent No.: US7498420.
20. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:0225-35; PMID:15737014; https://dx.doi/10.1371/journal.pmed.0020073
21. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102:7665-70; PMID:15897464; https://doi.org/10.1073/pnas.0502860102
22. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol 2015; 8:130; PMID:26692321; https://doi.org/10.1186/s13045-015-0227-0
23. Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 2015; 7:946-56; PMID:26083076; https://doi.org/10.1080/19420862.2015.1062192
24. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009; 50:886-91; PMID:19455460; https://doi.org/10.1080/10428190902943077
25. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 2016; 354:350-4; PMID:27608667; https://doi.org/10.1126/science.aag3267
26. Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch J V. Bispecific Anti-HIV-1 antibodies with enhanced breadth and potency. Cell 2016; 165:1609-20; PMID:27315478; https://doi.org/10.1016/j.cell.2016.04.050
27. Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Jonathan R, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 2015; 862:470-82; PMID:25774965; https://doi.org/10.1080/19420862.2015.1022694
28. Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, et al. Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies. J Immunol 2016; 196:3199-211; PMID:26921308; https://doi.org/10.4049/jimmunol.1501592
29. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; https://doi.org/10.1093/protein/gzh039
30. Davé E, Adams R, Zaccheo O, Carrington B, Compson JE, Dugdale S, Airey M, Malcolm S, Hailu H, Wild G, et al. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. MAbs 2016; 8:1319-35; PMID:27532598; https://doi.org/10.1080/19420862.2016.1210747
31. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; https://doi.org/10.1038/nbt.2797
32. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402; https://doi.org/10.4161/mabs.1.4.8755
33. Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, et al. Crystal structure of an Anti-Ang2 crossfab demonstrates complete structural and functional integrity of the variable domain. PLoS One 2013; 8:1-7; PMID:23613981; https://doi.org/10.1371/journal.pone.0061953
34. Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 2013; 32:5593-601; PMID:23812422; https://doi.org/10.1038/onc.2013.245
35. Parton RG, Schrotz P, Bucci C, Gruenberg J. Plasticity of early endosomes. J Cell Sci 1992; 103(Pt 2):335-48; PMID:1478937
36. St. Pierre CA, Leonard D, Corvera S, Kurt-Jones EA, Finberg RW. Antibodies to cell surface proteins redirect intracellular trafficking pathways. Exp Mol Pathol 2011; 91:723-32; PMID:21819978; https://doi.org/10.1016/j.yexmp.2011.05.011
37. Weflen AW, Baier N, Tang Q-J, Van den Hof M, Blumberg RS, Lencer WI, Massol RH. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell 2013; 24:2398-405; PMID:23741050; https://doi.org/10.1091/mbc.E13-04-0174
38. Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep 2005; 6:942-8; PMID:16113650; https://doi.org/10.1038/sj.embor.7400491
39. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs 2016; 8:1010-20; PMID:27285945; https://doi.org/10.1080/19420862.2016.1197457
40. Schuurman J, Parren PWHI. Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy? Curr Opin Immunol 2016; 40:vii-xiii; PMID:27083411; https://doi.org/10.1016/j.coi.2016.04.001
41. Sheridan C. Amgen's bispecific antibody puffs across finish line. Nat Biotechnol 2015; 33:219-21; PMID:25748895; https://doi.org/10.1038/nbt0315-219
42. Zlabinger GJ, Stuhlmeier KM, Eher R, Schmaldienst S, Klauser R, Vychytil A, Watschinger B, Traindl O, Kovarik J, Pohanka E. Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment. J Clin Immunol 1992; 12:170-7; PMID:1400897; https://doi.org/10.1007/BF00918085
43. Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20:509-15; PMID:2138557; https://doi.org/10.1002/eji.1830200308
44. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38; PMID:20305665; https://doi.org/10.1038/nrd3003